

Very High Dose Epinephrine for the Treatment of Vasoplegic Syndrome during Liver Transplantation

M. B. Khosravi^{1*}, S. Milani¹,
S. Ghaffaripour¹, A. Sahmeddini¹,
M. H. Eghbal¹, S. A. Malek-Hosseini²

¹Shiraz Anesthesiology and Critical Care
Research Center, Shiraz University of Medical
Sciences, Shiraz, Iran

²Department of Organ Transplantation, School
of Medicine, Shiraz University of Medical
Sciences, Shiraz, Iran.

ABSTRACT

A 55-year-old man with hepatitis B and hepatocellular carcinoma was treated with liver transplantation without veno-venous bypass. During the procedure his arterial blood pressure remained at 55/30 mm Hg and did not respond to increasing doses of norepinephrine. Vasoplegia was managed aggressively with the intravenous infusion of high doses of epinephrine.

KEYWORDS: Epinephrine; Hepatocellular carcinoma; Liver transplantation; Vasoplegia

INTRODUCTION

Norepinephrine-refractory vasoplegia (vasoplegic syndrome) has been reported in cardiac surgery [1]; the condition is similar to septic shock [2]. In the setting of liver transplantation, vasoplegic syndrome shares the hemodynamic characteristics of low systemic vascular resistance and high cardiac output. The mechanisms of refractory vasoplegia involve profound vasodilatation induced by nitric oxide and cyclic guanosine monophosphate [3]. However; vasoplegic syndrome differs from post-reperfusion syndrome in terms of its symptoms, etiology, and treatment [4].

CASE REPORT

A 55-year-old man (weight 80 kg, height 178 cm) with hepatitis B and hepatocellular carcinoma

was treated with liver transplantation without veno-venous bypass. He was ASA status III and MELD score 25. His preoperative serum creatinine was 1.08 mg/dL. Routine monitoring was established, then anesthesia was induced. Anesthesia was maintained with isoflurane, morphine and atracurium (intravenous bolus doses).

Approximately, 30 min after initiation of the operation, his arterial blood pressure rapidly dropped to 50/30 mm Hg. Infusion of norepinephrine (0.1–0.8 µg/kg/min) and dopamine (2.0 µg/kg/min) was started. After 45 min, the patient had still poor response to increasing doses of norepinephrine; the cardiac output was high (8.0 L/min), and the systemic vascular resistance was low (460 dyn s/cm⁵). Therefore, epinephrine was administered at a rate of 0.9 µg/kg/min; dopamine was also given at a rate of 2.0 µg/kg/min. Fluids were administered via rapid infusion system to maintain a central venous pressure in the range of 8–12 mm Hg.

The anhepatic phase took 68 min. After the suprahepatic and infrahepatic vena cava and

*Correspondence: Mohammad Bagher Khosravi, Shiraz Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Tel: + 98-711-233-7636

Fax: + 98-711-230-7072

E.mail: Kosravimb@Sums.ac.ir

Table 1: Evolution of the patient's intraoperative fluid intakes and outputs.

Fluids	Time (min)							Total
	60	120	180	240	300	360	390	
Blood loss (mL)	ND	2000	1000	3000	200	300	ND	6500
Packed RBC (U)	ND	ND	4	4	2	3	ND	13
Fresh frozen plasma (mL)	ND	ND	1000	400	200	400	ND	2000
Albumin (g)	10	10	10	10	10	10	ND	60
Fluids (mL)*	1500	2100	2400	1000	1000	1000	1000	10000
Urinary output (mL)	ND	5	3	32	80	76	54	250

ND: No data

*3000 mL half saline, 6000 mL normal saline

portal vein were unclaimed, the patient's need for epinephrine decreased.

Urine output was less than 1 mL/kg/min although the central venous pressure was maintained above 8 mm Hg and dopamine, furosemide and N-acetylcysteine were administered during the operation. Oxygen saturation and temperature remained within the normal range. Arterial blood gases and plasma potassium, sodium and hemoglobin also remained within acceptable ranges. The total operative time was 390 min (Table 1).

After surgery, the patient was transferred to the ICU, and epinephrine was infused in combination with dopamine 2.0 µg/kg/min to maintain the arterial blood pressure during the first 6 h of surgery. Continuous renal replacement therapy was initiated immediately post-operative in the ICU; the patient's endotracheal tube was removed 24 h later. On the first post-operative day, the serum creatinine level was 2.1 mg/dL; on the second day, it was 2.2 mg/dL. The patient was discharged from the ICU on day six with a serum creatinine level of 1.5 mg/dL. He was discharged from the hospital on post-operative day 20 without any further complications. After nine months

of follow-up, the BUN and creatinine were 16 mg/dL and 1.1 mg/dL, respectively.

DISCUSSION

Vasoplegic syndrome is generally characterized by persistent low arterial blood pressure (systolic pressure <60 mm Hg), increased cardiac output (cardiac index >2.5 L/min/m²) and decreased systemic vascular resistance (<800 dyne s/cm⁵). These alterations may persist despite intravenous infusion of ≥0.5 µg/kg/min norepinephrine. Vasoplegic differs from post-reperfusion syndrome in terms of its symptoms, etiology, and treatment [4-6].

The mechanism of vasoplegic syndrome is still unclear, but it may be related to surgical trauma, transfusion of blood components, liver and gastrointestinal tract ischemia, reperfusion injury, neuroendocrine disorder, systemic inflammatory response, endotoxemia, or other factors [4, 7]. The duration of vasoplegic syndrome significantly influences the outcome, so its prompt, accurate diagnosis and aggressive management are paramount to reduce its post-operative morbidity and mortality [1, 8]. Once the vasoplegia is identified, norepinph-

rine should be used as early as possible at a dosage up to 5.0 µg/kg/min [9]. In general, adrenalin is used when high-dose noradrenalin has failed [10]. Arginine vasopressin may be used as a supplement to catecholamines to reduce the dosage of norepinephrine or as a first-line treatment for vasoplegic syndrome [11]. In patients who do not respond to noradrenaline, methylene blue is a reasonable therapeutic choice [8, 12].

Our patient's arterial blood pressure decreased rapidly almost 30 min after the start of the operation to 50/30 mm Hg; the pressure responded poorly to volume infusions and increasing doses of norepinephrine (>0.5 µg/kg/min). Therefore, intravenous infusion of epinephrine was started at a rate of 0.9 µg/kg/min to maintain the arterial blood pressure during the next 3 h.

Previous studies recommended methylene blue to treat vasoplastic syndrome, but this drug was not available at the time our patient underwent liver transplantation, so we opted to use high-dose epinephrine. Norepinephrine, epinephrine and endothelin-1 are important elements in renal hypoperfusion and sodium-water retention in advanced cirrhosis [13, 16]. In decompensated patients, normalization of increased arterial blood pressure may increase renal perfusion and improve renal function [13, 17]. Maintaining blood pressure during liver transplantation appears to have a positive effect on peri-operative renal function. The use of high doses of epinephrine and norepinephrine for treating vasoplegic syndrome would probably increase blood pressure and improve renal function without increasing vasoconstriction in the splanchnic and renal vasculature, and thus without compromising liver and renal function.

After successful intra-operative management of vasoplegic syndrome in the course of liver transplant surgery, our patient was discharged from the hospital after 20 days without any complications.

ACKNOWLEDGMENTS

We would like to thank K. Shashok (AuthorAID in the Eastern Mediterranean) for improving the use of English in the manuscript, and M. Gholami at the Center for Development of Clinical Research of Nemazee Hospital for research assistance.

REFERENCES

- Gomes WJ, Carvalho AC, Palma JH, et al. Vasoplegic syndrome after open heart surgery. *J Cardiovasc Surg (Torino)* 1998;**39**:619-23.
- Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008;**358**:877-80
- Koelzow H, Gedney JA, Baumann J, et al. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. *Anesth Analg* 2002;**94**:824-9
- Ulukaya S, Alper I, Aydin U, Kilic M. Successful resuscitation of cardiac arrest due to postreperfusion syndrome during orthotopic liver transplantation: a case report. *Transplant Proc* 2007;**39**:3527-9
- Hilmi I, Horton CN, Planinsic RM, et al. The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation. *Liver Transpl* 2008;**14**:504-8
- Cao Z, Tao G. Is it possible to distinguish between vasoplegic syndrome and postreperfusion syndrome during liver graft reperfusion? In response. *Anesth Analg* 2010;**110**:970-1
- Pillay SP, Wynter C, Lynch S, et al. Endotoxin levels in donors and recipients during orthotopic liver transplantation. *Aust N Z J Surg* 1997;**67**:187-91
- Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. *J Thorac Cardiovasc Surg* 1998;**116**:973-80
- Nygren A, Thorén A, Ricksten SE. Norepinephrine and intestinal mucosal perfusion in vasodilatory shock after cardiac surgery. *Shock* 2007;**28**:536-43
- Xu X, Ling Q, Wei Q, et al. An effective model for predicting acute kidney injury after liver transplantation. *Hepatobiliary Pancreat Dis Int* 2010;**9**:259-63
- Dunser MW, Westphal M. Arginine vasopressin in vasodilatory shock: effects on metabolism and beyond. *Curr Opin Anesthesiol* 2008;**21**:122-7
- Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. *Ann Thorac Surg* 2004;**77**:496-9

13. Henriksen JH, Moller S. Liver cirrhosis and arterial hypertension. *World J Gastroenterol* 2006;**12**:678-85
14. Ring-Larsen H, Henriksen JH. Pathogenesis of ascites formation and hepatorenal syndrome: humoral and hemodynamic factors. *Semin Liver Dis* 1986;**6**:341-52
15. Moore K. Endothelin and vascular function in liver disease. *Gut* 2004;**53**:159-61
16. Møller S, Gülberg V, Henriksen JH, Gerbes AL. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. *J Hepatol* 1995;**23**:135-44
17. Henriksen JH, Ring-Larsen H. Renal effects of drugs used in the treatment of portal hypertension. *Hepatology* 1993;**18**:688-95

Archive of SID